September 5, 2016 – UT Southwestern investigators report in Nature a new class of drugs against renal cancer, HIF-2 inhibitors, which are more efficacious and better tolerated than sunitinib. Press Release
August 1, 2016 – The KCP is awarded an $11 million Specialized Program of Research Excellence (SPORE) grant for translational kidney cancer research. This is only the second SPORE grant awarded for kidney cancer in the history of NCI’s Translational Research Program, and the first awarded to a single institution.
June 15, 2016 – The KCP works with the Office of Quality Improvement to develop protocols for measuring outcomes across cancer types.
June 10, 2016 – The KCP works with the Office of Information Systems to develop protocols to automatically extract information from the electronic medical record that can be linked to research samples and genomics.
June 3, 2016 – Dr. Kevin Courtney presents results from the Phase I trial of a first-in-class oral HIF-2a inhibitor at the 2016 ASCO meeting in Chicago; the trial showed that the inhibitor is safe and had activity in heavily pretreated patients with advanced ccRCC.
June 1, 2016 – Dr. Hans Hammers, who led the kidney cancer oncology program at Johns Hopkins, joins the UTSW Kidney Cancer Program as a Co-Leader for clinical research. Dr. Hammers is the recipient of the inaugural Eugene P. Frenkel Endowed Scholar Award. His research program focuses on immunotherapy for kidney cancer. We are thrilled to have him join the KCP.
May 19, 2016 – The KCP hosts Dr. Fraydoon Rastinejad, Professor at Sanford-Burnham-Prebys, who discusses novel vulnerabilities in HIF transcription factors, which are key drivers of renal cancer development.
April 2016 – Dr. Hannan, along with Drs. Pedrosa and Cadeddu, is awarded a Research Scholar Grant from the American Cancer Society to support a clinical trial that evaluates stereotactic radiation for small renal masses. Clinical Trial
April 11, 2016 – Dr. Courtney is awarded a $50,000 grant from the Friends of the Comprehensive Cancer Center to support a pilot clinical trial comparing two PET/CT imaging modalities in patients with metastatic RCC receiving standard of care systemic treatment.
March 2016 – Yu and colleagues identify IGFBP5 as a potential tumor suppressor protein downstream of mTORC1 that blocks IGF-1 signaling. Abstract
February 16, 2016 – The Integration Panel for Congressionally-Directed Medical Research Programs for cancer, which Dr. Brugarolas serves on, allocates $50 million to support cancer research and sets the vision for next fiscal year.
January 27, 2016 – A multimodality meeting was held with neurosurgeons, radiation oncologists, and medical oncologists to review UTSW experience in spinal metastases management.
January 14, 2016 – Dr. Mendell reports in Cell the discovery of a noncoding RNA, NORAD, that is required to maintain genomic stability.
January 1, 2016 – John Abrams, Ph.D., reports that p53 mutations may contribute to Wilms tumor development by increasing retrotransposon activity. Abstract
December 18, 2015 – Congress passes the omnibus spending bill, which includes a $2 billion increase to the NIH budget. The bill contains language that encourages increased funding for kidney cancer research. Press Release
December 8, 2015 – Joshua Mendell, M.D., Ph.D., is selected by the The Academy of Medicine, Engineering, and Science of Texas (TAMEST) to receive the 2016 Edith and Peter O'Donnell Award in Medicine. Press Release • Video
November 23, 2015 – The Cancer Prevention and Research Institute of Texas (CPRIT) awards $19.6 million in research grants to several UT Southwestern researchers including KCP Program Leader James Brugarolas, M.D., Ph.D., KCP Co-Leader (Metabolism) Ralph DeBerardinis, M.D., Ph.D., and KCP members Thomas Carroll, Ph.D., Joshua Mendell, M.D., Ph.D., and W. Lee Kraus, Ph.D. Press Release
November 15, 2015 – UT Southwestern team of urologists identifies selected population that might benefit from kidney cancer screening. Abstract
November 4, 2015 – Brugarolas Lab hosts first lab tour for participants of the KCP Annual Event.
October 15, 2015 – Andy Geisse, former CEO of AT&T Business Solutions, accepts nomination to direct new KCP Advisory Committee.
October 2, 2015 – Dr. Brugarolas is informed by the NIH that the UT Southwestern Specialized Program of Research Excellence (SPORE) application in Kidney Cancer received a score of 14 putting it in the high-impact, exceptional category, the highest possible scoring category. Notification of awards will be made in spring of 2016.
September, 2015 – Dr. Carlos Bagley, Director of the Spine Center at Duke University Medical Center, joins the UT Southwestern faculty to direct the Neurological Surgery Spine Program and serve as Vice Chair of the Department of Neurosurgery.
August 1, 2015 – On August 1, 2015, the Kidney Cancer Program held its annual event at the A.W. Harris Faculty Club at UT Southwestern. More than 160 patients and their family members attended, as well as KCP clinicians and researchers. Video • Photos
July 20, 2015 – Nivolumab is shown to improve the survival of patients with metastatic kidney cancer in trial that UT Southwestern participated in. Press Release
July 10, 2015 – The Harold C. Simmons Comprehensive Cancer Center is awarded "Comprehensive" designation by the National Cancer Institute, becoming the first and only facility to have this distinction in North Texas. Press Release • Video
May 19, 2015 – Joshua Mendell, M.D., Ph.D., a key investigator in the KCP Pediatric Kidney Tumor group, is named Howard Hughes Medical Institute Investigator. Press Release
February 13, 2015 – Dr. Brugarolas participates in the Vision Setting Meeting for Congressionally-Directed Medical Research Programs for cancer.
January 26, 2015 – KCP Monthly Research Seminar Series begins with inaugural presentation by Ivan Pedrosa, M.D.
January 26, 2015 – Three members of the KCP Patient Council, Mrs. Sophia Moschos and Mrs. and Mr. Tony Towler start volunteering in the Simmons Cancer Center Clinics.
June 9, 2016 – Drs. Brugarolas, Cadeddu, Courtney, and Lotan, along with several other UT Southwestern faculty, speak at the 2016 annual meeting of the Texas Urological Society held in Dallas.
June 3, 2016 – Dr. Courtney presents results from the Phase I trial of a first-in-class oral HIF-2a inhibitor in patients with advanced ccRCC at the 2016 ASCO meeting held in Chicago.
May 6, 2016 – Dr. Brugarolas discusses personalized medicine for renal cell carcinoma at the American Urological Association's 2016 Annual Meeting in San Diego.
April 7, 2016 – Dr. DeBerardinis gives a keynote presentation on a systems approach to the study of cancer metabolism at the 12th International VHL Medical Symposium in Boston, where Dr. Brugarolas discusses advances in kidney cancer.
March 5, 2016 – Dr. DeBerardinis presents his work on metabolism and tumor growth at the Fondation IPSEN Conference on Tumor Metabolism in San Pedro de Atacama, Chile.
February 22, 2016 – Dr. DeBerardinis gives a talk entitled "Understanding Metabolic Heterogeneity in Cancer Cells and Tumors" at the Keystone Symposium in Banff, Alberta, Canada.
February 12, 2016 – Dr. Brugarolas chairs a session and gives a presentation at the American Association for Cancer Research meeting in New Orleans on modeling cancer in mice.
November 20, 2015 – Dr. Brugarolas speaks about discoveries and future directions in the molecular genetics of kidney cancer at the 6th Scientific SOGUG Symposium in Madrid, Spain.
November 6–7, 2015 – Dr. Kapur speaks about "Chromophobe RCC", Dr. Margulis participates in a debate on "Optimal Treatment for cT1b Renal Mass in Patient with Normal GFR", and Dr. Brugarolas moderates the session "RCC: Biology and Targets" at the Fourteenth International Kidney Cancer Symposium held in Miami, FL. Slides - Kapur
October 23, 2015 – Dr. DeBerardinis presents his work – Metabolic Heterogeneity in Cancer Cells and Tumors – at the Fourth AACR International Conference on Frontiers in Basic Cancer Research held in Philadelphia, PA.
September 15, 2015 – Dr. Brugarolas addresses the UT Southwestern President's Research Council about kidney cancer. Video
September 7, 2015 – Dr. Brugarolas presents his work on BAP1 (BAP1: Lessons from Renal Cell Carcinoma) at the 16th World Conference on Lung Cancer held in Denver, Colorado.
April 24, 2015 – Dr. Brugarolas (despite his laryngitis) speaks on clinical implications of kidney cancer genes at the Tenth European International Kidney Cancer Symposium in Lyon, France. Video • Slides
January 23, 2015 – Dr. Brugarolas discusses advances towards personalized medicine for kidney cancer patients at the Annual Meeting of the Academy of Medicine, Engineering & Science of Texas in Houston, TX. Video